A First-in-Class Selective and Potent IRAK4 Degrader Case Study
A First-in-Class Selective and Potent IRAK4 Degrader Case Study
14 PagesIRAK4 as a clinically validated target. Biology of targeted protein degradation. IRAK4 degradation leads to superior activity compared to kinase inhibition. In vivo anti-inflammatory activity of oral IRAK4 degrader.
